Human microbiome, applied to clinical practice

The aim of review. The Human microbiome project was designed for identification and characterization of set of human microorganisms as well as for studying the changes in the human health due to microbiome changes. The Human Genome Project assumes: development of the human genome variations database (HapMap; Human Variome Project), interpretation of human phenotype differences (Encyclopedia Of DNA Elements), modeling of human phenomenon (RECON), interpretation of epigenetic variants and hereditary changes in phenotypical manifestations. The Human Microbiome Project became the sequel of The Human Genome Project. Summary. The human microbiome represents a variety of microbial species with the differing metabolic activity. The main features of human microbiome include: great variety at the level of genus and at the level of species, varying modes of diversification within samples, variability of microbiome of separate individuals is much less in comparison to interindividual variability, metabolic pathways remain unchanged until the patient is healthy, the lack of pathogenic bacteria in healthy microbiomes serves as microbiota alteration evidence in the state of disease. Identification of «microbial core» in microbial taxon remains a fundamental problem. There is a need to study of possible effects of altered microbiome on drug interactions and the immune status. The model of bacterial involvement in colorectal cancer progression is under study. Besides, the increasing attention of doctors and scientists is attracted to the issue intestinal microflora changes at antibiotic treatment. Conclusion. «The Human microbiome project» is implemented within identification and characterization of the microorganisms associated to the different anatomical regions of the human body tasks of the project include the study of inand interindividual microbiome disorders and their possible effect on the human health. The theory and practice of microbiome causes high potential for justification of the pattern of healthy nutritional pattern, behavior and development of new therapeutic agents.

микробиом человека, проект человеческого генома, микробиота, колоректальный рак, антибиотикотерапия, пробиотики, пребиотики

1. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T. et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-80.

2. Castellarin M., Warren R.L., Freeman J.D., Dreolini L., Krzywinski M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.

3. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009;106:14728-33.

4. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011;108:4554-61.

5. Dutlih B.E., Backus L., Hijum S.A., Tjalsma H. Screening metatranscriptomes for toxin genes as functional drivers of human colorectal cancer. Best Pract Res Clin Gastroenterol 2013;27:85-99.

6. El-Rakaiby M., Dutlih B.E., Rizkallah M.R., Boleij A., Cole J.N., Aziz R.K. Pharmacomicrobiomics: The impact of human microbiome variations on system pharmacology and personalized therapeutics. OMICS 2014;18:402-14.

7. Geng J., Fan H., Tang X., Zhai H., Zhang Z. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog 2013;5:2.

8. Haiser H.J., Gootenberg D.B., Chatman K., Sirasani G., Balskus R.P., Turnbaugh P.J. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lensa. Science 2013;341:295-8.

9. Huse S.M., Ye Y., Zhou Y., Fodor A.A. A core human microbiome as viewed through 165 rRNA sequence clusters. PLoS ONE 2012;7:e34242.

10. Jacobsson H.E., Jernberg C., Andersson A.F., SjolundKarlsson M., Jansson J.K. Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE 2010;5:e9836.

11. James L.P. Metabolomics: Integration of a new «omics» with clinical pharmacology. Clin Pharmacol Ther 2013;94:547-51.

12. Kostic A.D., Chun E., Robertson L., Glickman J.N., Gallini C.A., Michaud M., Clancy T.E. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.

13. Li K., Bihan M., Methe B.A. Analyses of the stability and core taxonomic memberships of the human microbiome. PLoS ONE 2013;8: e63139.

14. Rubinstein M.R., Wang X., Liu W., Hao Y., Cai G., Han Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesion. Cell Host Microb 2013;14:195-206.

15. Tjalsma H., Boleij A., Marchesi J.R., Dutlih B.E. A bacterial driver-passenger model for colorectal cancer: Beyond the usual suspects. Nat Rev Microbiol 2012;10:57582.

16. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillere R., Hannani D., Enot D.P., Pfirschke C. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-6.

17. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y., Keilbaugh S.A., Bewtra M. et al. Linking long-term dietary with gut microbial enterotypes. Science 2011;334:105-8.

18. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.

19. Zackular J.P., Baxter N.T., Iverson K.D., Sadler W.D., Petrosino J.F., Chen G.Y., Schloss P.D. The gut microbiome modulates colon tumorigenesis. MBio 2013;4:e00692-00713.